Drug Profile
Estradiol 3-phosphate controlled-release - Redwood Pharma
Alternative Names: 17beta-Estradiol-3-phosphate; Estradiol, 3-(dihydrogen phosphate); Estradiol-3-phosphate; RP101 - Redwood PharmaLatest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Redwood Pharma
- Class Estradiol congeners; Eye disorder therapies; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Dry eyes
Highest Development Phases
- Phase II Dry eyes
Most Recent Events
- 25 Jul 2022 No development reported - Phase-II for Dry eyes (In children, In the elderly, In adults) in Hungary, Germany, Austria (Ophthalmic)
- 22 Mar 2021 Safety and efficacy data from phase II trial in Dry eye disease released by Redwood Pharma
- 28 Dec 2020 Efficacy data from a phase II trial in Dry eyes released by Redwood Pharma